NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Zhengye Biotechnology Holding Limited ZYBT
4 fiscal years on record · CNY · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
¥116.4M
▼ 37.6% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-26.1%
Net margin · FY25
-60.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CNY 116.4M
Revenue, FY2025 · full 4-year series below
Revenue
Net income
The company lost 60 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-26.1%
Return on equity, FY2025
ROE
Operating margin-60.6%
Net margin-60.0%
Return on assets-15.0%
Each CNY of equity lost 26 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−23.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CNY 436.5M
total assets, end of FY2025
Total assetsCNY 436.5M
EquityCNY 249.8M
CashCNY 50.3M
Gross debtCNY 10.2M
Net debtCNY -40.1M
Current ratio1.14×
The company holds more cash than debt.
History
4 fiscal years
Every figure from documents filed with the SEC · CNY
Metric
2025
2024
2023
2022
Revenue ¥B
0.1
0.2
0.2
0.3
Operating income ¥B
−0.1
0.0
0.0
0.1
EBITDA ¥B
−0.0
0.0
0.1
0.1
Income tax ¥B
0.0
0.0
0.0
0.0
Net income ¥B
−0.1
0.0
0.0
0.0
EPS, diluted ¥
·
0.25
0.69
1.02
Dividend / sh ¥
·
·
·
·
Payout %
·
142
125
46
ROE %
−26.1
4.1
11.5
·
Shares out B
·
0.05
0.05
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
13 of 13
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed